Prelude Therapeutics Expects $142.7 Million To Last Into 2028 As Breast-Cancer Testing Begins

Initial breast-cancer clinical data are expected in the second half of 2027, with research spending lower after earlier cuts.

Share
Prelude Therapeutics Expects $142.7 Million To Last Into 2028 As Breast-Cancer Testing Begins

Prelude Therapeutics, which develops experimental cancer medicines, reported $142.7 million in cash, cash equivalents, restricted cash and securities in Monday's SEC filing. Management expects those resources to support operations into the second quarter of 2028, beyond its planned initial breast-cancer trial readout in the second half of 2027.

Breast-cancer enrollment gets underway

Prelude began enrolling patients in the fourth quarter in an early-stage study of PRT13722, its pill targeting the KAT6A protein in hormone-receptor-positive breast cancer. Its earnings release set the expected timing for initial evidence of clinical activity at the second half of 2027.

The FDA cleared human testing on September 10. An October agreement with Lilly supplies abemaciclib, marketed as Verzenio, and imlunestrant, marketed as Inluriyo, for combinations in the existing trial involving hormone-receptor-positive, HER2-negative breast cancer.

Prelude retains global development and commercial rights to PRT13722. Its November presentation describes testing the pill alone and with other treatments, assessing safety, responses and how long those responses last.

Earlier cuts reduce quarterly spending

Third-quarter research spending fell to $14.8 million from $21.7 million a year earlier. Prelude attributed the decline primarily to lower costs for SMARCA2 trials paused in 2025 and employee costs following workforce reductions in the second half of that year.

Total operating expenses fell to $19.9 million from $26.9 million. Administrative spending eased to $5.1 million from $5.2 million, which the company attributed mainly to lower professional fees and employee costs.

The unaudited quarterly loss narrowed to $12.5 million, or $0.12 per share, from $19.7 million, or $0.26 per share. Revenue declined to $5.6 million from $6.5 million.

The loss included $2.0 million in non-cash stock pay, versus $2.4 million a year earlier. Research stock pay fell to $0.9 million from $1.4 million; administrative stock pay rose to $1.1 million from $1.0 million.

Blood-cancer data and an Incyte deadline

Prelude continues enrolling patients with polycythemia vera and myelofibrosis in its early-stage PRT12396 study. The treatment targets the JAK2V617F mutation, and the company anticipates early trial data in 2027 in its development schedule.

Incyte's exclusive option to buy the JAK2 program, announced in November 2025, expires in February 2027, with a possible three-month extension. Prelude also develops antibody-carried drug payloads, licenses technology to partners including AbCellera, and controls its own program targeting mutated calreticulin in blood cancers.

Chief Executive Officer Kris Vaddi said of that calreticulin program, "we look forward to presenting its first preclinical data at ASH in December." The American Society of Hematology meeting in New Orleans runs December 12–15 and will also feature a poster describing the PRT12396 trial.

Prelude's breast-cancer program also has updated preclinical findings and a trial-description poster accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8–11.

Sources